Sector
PharmaceuticalsOpen
₹18.35Prev. Close
₹17.85Turnover(Lac.)
₹27.95Day's High
₹18.35Day's Low
₹16.5652 Week's High
₹33.4952 Week's Low
₹16.8Book Value
₹19.2Face Value
₹10Mkt Cap (₹ Cr.)
86.27P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 50.1 | 50.1 | 50.1 | 40.67 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 46.58 | 68.18 | 107.78 | 118.24 |
Net Worth | 96.68 | 118.28 | 157.88 | 158.91 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 202.37 | 167.25 | 169.57 | 243.52 |
yoy growth (%) | 20.99 | -1.36 | -30.36 | 22.52 |
Raw materials | -112.35 | -94.65 | -127.94 | -171.5 |
As % of sales | 55.51 | 56.59 | 75.45 | 70.42 |
Employee costs | -14.01 | -13.41 | -11.73 | -10.27 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 29.49 | 4.73 | -16.1 | 15.23 |
Depreciation | -15.82 | -17.33 | -19.3 | -18.16 |
Tax paid | -6.71 | -1.1 | 4.07 | -2.89 |
Working capital | 9.02 | 16.64 | -30.71 | 3.77 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 20.99 | -1.36 | -30.36 | 22.52 |
Op profit growth | 57.67 | 169.55 | -73.11 | -9.21 |
EBIT growth | 144.96 | -414.59 | -115.35 | -33.57 |
Net profit growth | 527.76 | -130.15 | -197.49 | 422.36 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,787.4 | 137.43 | 4,32,960 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,012.5 | 79.59 | 1,65,003.32 | 594 | 0.48 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,525.9 | 26.47 | 1,23,201.99 | 1,438.15 | 0.85 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,238.9 | 60.04 | 1,09,514.33 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,557.5 | 55.53 | 1,07,385.94 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Omkar P Herlekar
Independent Director
Hardesh Tolani
Independent Director
Ajay Sukhwani
Independent Director
Ekta Gurnasinghani
Company Sec. & Compli. Officer
Mitti M Jain
Independent Director
Manali Bhagtani
Whole Time Director
Umesh S. Pawar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Lasa Supergenerics Ltd
Summary
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra. It specialises in catalyst chemistry and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain, the Company is fully backward integrated for its key molecules-from discovery research up to full-scale bulk production. The Companys marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future.The Company announced the launching of 2 new block buster products with all-time strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Comp
Read More
The Lasa Supergenerics Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹17.22 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lasa Supergenerics Ltd is ₹86.27 Cr. as of 25 Apr ‘25
The PE and PB ratios of Lasa Supergenerics Ltd is 0 and 0.99 as of 25 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Lasa Supergenerics Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lasa Supergenerics Ltd is ₹16.8 and ₹33.49 as of 25 Apr ‘25
Lasa Supergenerics Ltd's CAGR for 5 Years at -13.16%, 3 Years at -32.03%, 1 Year at -30.41%, 6 Month at -28.66%, 3 Month at -31.77% and 1 Month at -9.53%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.